Since discovery of the first RET fusion in thyroid cancers, at least 13 fusion partners have been identified in papillary thyroid cancers, the most common of which are coiled-coil domain containing 6 (CCDC6-RET) and nuclear receptor co-activator 4 (NCOA4)-RET (40). This evidence concerns the gene RET and thyroid gland papillary carcinoma.